655 related articles for article (PubMed ID: 9153367)
1. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
3. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
4. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
Pittet D; Harbarth S; Suter PM; Reinhart K; Leighton A; Barker C; Macdonald F; Abraham E
Am J Respir Crit Care Med; 1999 Sep; 160(3):852-7. PubMed ID: 10471608
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
[TBL] [Abstract][Full Text] [Related]
6. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
Cohen J; Carlet J
Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
[TBL] [Abstract][Full Text] [Related]
7. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
Fisher CJ; Dhainaut JF; Opal SM; Pribble JP; Balk RA; Slotman GJ; Iberti TJ; Rackow EC; Shapiro MJ; Greenman RL
JAMA; 1994 Jun; 271(23):1836-43. PubMed ID: 8196140
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
[TBL] [Abstract][Full Text] [Related]
10. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
[TBL] [Abstract][Full Text] [Related]
11. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
[TBL] [Abstract][Full Text] [Related]
12. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
Schuster DP; Metzler M; Opal S; Lowry S; Balk R; Abraham E; Levy H; Slotman G; Coyne E; Souza S; Pribble J;
Crit Care Med; 2003 Jun; 31(6):1612-9. PubMed ID: 12794395
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Abraham E; Naum C; Bandi V; Gervich D; Lowry SF; Wunderink R; Schein RM; Macias W; Skerjanec S; Dmitrienko A; Farid N; Forgue ST; Jiang F
Crit Care Med; 2003 Mar; 31(3):718-28. PubMed ID: 12626975
[TBL] [Abstract][Full Text] [Related]
14. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
[TBL] [Abstract][Full Text] [Related]
15. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
[TBL] [Abstract][Full Text] [Related]
17. Does N-acetyl-L-cysteine influence cytokine response during early human septic shock?
Spapen H; Zhang H; Demanet C; Vleminckx W; Vincent JL; Huyghens L
Chest; 1998 Jun; 113(6):1616-24. PubMed ID: 9631802
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
[TBL] [Abstract][Full Text] [Related]
19. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis.
Oberholzer A; Souza SM; Tschoeke SK; Oberholzer C; Abouhamze A; Pribble JP; Moldawer LL
Shock; 2005 Jun; 23(6):488-93. PubMed ID: 15897799
[TBL] [Abstract][Full Text] [Related]
20. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]